cyrilzakka/clinical-trials huggingface dataset:
Posttraumatic Stress Symptoms Among Rescuers at Risk

This cross-sectional, anonymous online survey aims to examine how salient variables influence PTSS, well-being, and suicidal ideation across the following professions of rescue workers: firefighters, ambulance personnel, police officers, and emergency and psychiatric nurses. PTSS, coping strategies, well-being, suicidal ideation, previously experienced and work-related trauma, and self-efficacy were measured and analyzed using multiple regression and structural equation modeling.

Employees of rescue and emergency services are at a risk of posttraumatic stress symptoms (PTSS) due to exposure to trauma and work-related stressors. Salient predictors for the development of PTSS among rescue workers have been identified; however, little is known about how predictors (e.g. coping strategies) differ among professions requiring repeated engagement in emergencies. The present survey examines how these variables influence PTSS, well-being, and suicidal ideation across different professions of rescue Workers using multiple regression and structural equation modeling.

Eligibility Criteria:
Inclusion Criteria:

Employee at the rescue or emergency services. The participation in the anonymous online study is voluntary and promoted by the department heads at the places of work corresponding to the studied professions. No ethical approval is needed as the survey was voluntary and anonymous and participants gave consent to use the data with their participation.

Exclusion Criteria:

* None
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).

Eligible participants will be maintained on ART and receive either one infusion (Part 1) or multiple infusions of MGD014 (Part 2). Part 1 is a single ascending dose study with a 1+3 design for the first 2 dose cohorts, and a 3+3 design with staggered accrual for the 6 higher dose cohorts, with an aim of determining the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending doses up to either the Optimal Biologic Dose (OBD) or the maximum administered dose (MAD).

Part 2 is a multi-dose expansion cohort with MGD014 administered at the OBD, as determined in Part 1. In Part 2, additional assessments on the effects of MGD014 on HIV latent infection parameters will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Ability and willingness of participant to provide written informed consent.
* HIV-1 infection, documented by any FDA-approved rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.
* On a potent, stable, continuous ART regimen for ≥ 24 months prior to Screening.
* Plasma HIV-1 RNA \< 50 copies/mL at two time points in the previous 12 months prior to screening (one time point can be screening) and never ≥ 50 copies/mL on 2 consecutive time points in the last 24 months.
* Adequate organ function based on acceptable laboratory parameters.

Exclusion Criteria:

* Women of childbearing potential defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or menopause.
* History or other evidence of severe illness, immunodeficiency other than HIV, or any other condition that would make the potential participant unsuitable for study.
* History or other evidence of any condition or process for which signs or symptoms could be confused with reactions to MGD014.
* History of any HIV immunotherapy or HIV vaccine except for MGD014 within 12 months prior to screening.
* History of clinically significant cardiovascular disease, severe allergic reactions, malignancy (except non-melanoma skin cancer) within 5 years, seizure disorder within 2 years, organ/tissue transplant, autoimmune disease, unstable asthma, bleeding disorder.
* Evidence of active viral, or antifungal treatment within 7 days prior to the initiation of study drug
* Active, asymptomatic, or suspected COVID-19/SARS-CoV-2 infection.
* Active, untreated syphilis.
* Use of blood products, cytokine therapy, growth-stimulating factors, cytotoxic chemotherapy or investigational therapy within 90 days.
* Current use of the antivirals maraviroc and/or enfuvirtide.
* Any vaccination with exception of flu vaccine within 30 days of screening.
Electronic Support for Pulmonary Embolism Emergency Disposition

To evaluate the impact of an integrated electronic clinical decision support system to facilitate risk stratification and site-of-care decision-making for patients with acute pulmonary embolism.

Many low-risk emergency department patients with acute pulmonary embolism are routinely hospitalized despite being eligible for outpatient care. One impediment to home discharge is the difficulty of identifying which patients can safely forego hospitalization. This pragmatic clinical trial intends to evaluate the effect on emergency department disposition of a multicomponent intervention, including electronic clinical decision support system access, physician education, and physician-specific audit and feedback. The hypothesis for this study is that intervention sites, when compared with concurrent control sites, will see an increase in home discharges without an increase in 5-day pulmonary embolism-related return visits or 30-day all-cause mortality.

Eligibility Criteria:
Inclusion Criteria:

* Acute objectively-confirmed pulmonary embolism, diagnosed in the emergency department

Exclusion Criteria:

* Comfort-care only
* Left the ED against medical advice
* Current PE radiologically diagnosed \>12 hrs prior to arrival
* Recent DVT or PE diagnosed within 30 days
* Pregnant
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI). Cetuximab is a protein that is designed to block a substance in cancer cells called "epidermal growth factor receptor" or EGFR. EGFR helps cancer cells grow.

* Participants on this study will receive cetuximab by infusion intravenously once per week and may continue to receive weekly cetuximab infusions until their disease progresses or they experience unacceptable side effects.
* The following will be performed every 4 weeks while they are receiving study treatments: Physical examination; performance status; and blood work. A CT scan of the chest and upper abdomen will be performed every 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed stage IIIB or IV recurrent or progressive NSCLC
* Patients must have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the EGFR pathway
* Measurable disease, as defined by RECIST criteria
* Patients must have a suitable frozen or paraffin-embedded tissue sample available for EGFR mutational analysis. Prior EGFR mutational analyses are allowable
* Patients with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be clinically stable
* ECOG Performance Status 0-2
* 18 years of age or older
* Negative pregnancy test within 7 days of treatment or be categorized as not of child-bearing potential
* Bone marrow function, renal function, hepatic function as outlined in protocol

Exclusion Criteria:

* Women who are pregnant of breastfeeding
* Active concurrent malignancy
* Major thoracic or abdominal surgery within 30 days prior to the first infusion of cetuximab
* Significant history of uncontrolled cardiac disease
* Uncontrolled seizure disorder, or active neurological disease
* Prior severe infusion reactions to a monoclonal antibody
* Prior chemotherapy regimen within 21 days prior to study entry
* Any EGFR tyrosine kinase inhibitor within 14 days of study entry
* Radiation therapy within 14 days prior to the first infusion of cetuximab
* Acute hepatitis or known HIV
* Active or uncontrolled infection
* Any concurrent chemotherapy or any other investigational agent(s)
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and on bone turnover.

This study is will assess the safety and efficacy of Zoledronic acid 4 mg, given every 3 months over 24 months, in improving bone mineral density in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment compared to placebo.

This study is not recruiting patients in the United States.


Eligibility Criteria:
Inclusion Criteria:

* Female patients with histologically confirmed incident invasive breast cancer (T1-4) with no evidence of regional lymph node metastasis (N0) or distant metastasis (M0) and after complete primary tumor resection and axillary lymph node dissection less than 90 days before start of study drug treatment.
* Hormone receptor status is negative
* Patient is premenopausal (spontaneous and regular menses with premenopausal estradiol levels (\>10ng/dL)
* Patient receives adjuvant standard chemotherapy with approved cytotoxic chemotherapeutic drugs (e.g. AC 4-6 cycles) (prior neoadjuvant CT is allowed)
* Bone density at study entry \> -2.5 T-Score

Exclusion Criteria:

* Prior treatment with bisphosphonates and estrogens or treatments for osteoporosis in addition to calcium and vitamin D
* Severe physical or psychological concomitant diseases and other known concurrent, severe medical disorder jeopardizing the life of the patient in the immediate future (e.g., myocardial infarction in previous six months, angina pectoris despite treatment, uncontrolled severe arterial hypertension, progressive cardiac or respiratory failure)
* Known hypersensitivity to bisphosphonates
* Abnormal renal function
* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures and recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
Single Dose Pharmacokinetics of Egalet® Oxycodone

The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet® oxycodone formulations and compare to a marketed oxycodone product.


Eligibility Criteria:
Main inclusion criteria:

* ≥18 years and ≤55 years
* Non-smoker
* BMI ≥18.0 and ≤30.0

Main exclusion criteria:

* Any clinically significant abnormality or abnormal laboratory test results found during medical screening
* History of allergic reactions to opioids or other related drugs
* History of significant alcohol abuse or drug abuse
* Use of any drugs known to inhibit hepatic drug metabolism
* Pregnant or breast-feeding
Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes

The primary purpose of this study is to assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein isolation with radiofrequency ablation.

The purpose of this study is:

1. To assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein isolation with radiofrequency ablation.
2. To measure the inflammatory cytokine (TNF-α, IL-1, IL-6, IL-8) response to radiofrequency ablation for atrial fibrillation with or without prior prednisone treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Able to provide written informed consent;
2. Scheduled for radiofrequency ablation procedure for treatment of atrial fibrillation

Exclusion Criteria:

1. History of heart failure (right or left or biventricular) or cardiomyopathy.
2. Immunosuppressive disorders and systemic fungal infection
3. Concurrent use of corticosteroids in one week prior recruitment.
4. Allergy or prednisone or its components.
5. Other medical conditions were use of corticosteroids is not recommended or contraindicated.
6. Patients with chronic and permanent atrial fibrillation.
7. Patients with established diagnosis of rheumatological and immunological disorders.
A Study of Latin Dance for Post- Lung Transplant

The purpose of this research study is to see if participating in Latin dance for 12 sessions can improve wellbeing in several areas including balance, fear of movement, anxiety, depression and spirometry.


Eligibility Criteria:
Inclusion Criteria:

- Ambulatory with or without assisting devices (not on supplemental oxygen is not exclusionary), who have completed outpatient cardiopulmonary rehab and good pain control.

Exclusion Criteria:

- Tracheostomy, Hemodialysis, gastro-jejunal tubes, nasogastric tubes, wound vacs, chest tube, high levels of oxygen supplementation (mask vs nasal canula), recent falls.
Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial）

The fight against the spread of the 2019-nCoV epidemic has achieved some success in China, but the epidemic is far from over. A key factor making the epidemic under control in China is the government's call for social distance, which has led to few people going out for donation. As a result, the number of blood donors on the streets has been continuing to decline. The first urgent recruitment of blood donors had been implemented during the period from 30 April to 10 May via emergency recruitment SMS . This repeat trial has been designed to further confirm the results from the the first recruitment by comparing which information extraction frameworks would be more sensitive to blood donors in emergency situations.

Researches has showed that that the information extraction and processing in emergency was different from the normal situation. To understand what information the blood donors are more sensitive to in an environment that may pose a potential threat to themselves, the first urgent recruitment of blood donors had been implemented during the period from 30 April to 10 . This interventional study is the repeat trail of the first trail. The same with first trail, eligible blood donors in Guangzhou Blood Center has been randomly divided into four groups according to their sociological variables, their interval since last blood donation , their history donation times and the location of their last blood donation. Three groups of donors has been randomly selected as interventional groups, and will receive three kindly of emergency blood donor recruitment SMS respectively. The placebo group donors will only receive a thank-you SMS. One recruitment SMS will emphasize what blood services will do to ensure the safety of blood donors during their donation in 2019-nCoV epidemic,one will shows information about a loss-based framework, while the third one will show information about a benefit-based framework .

Eligibility Criteria:
Inclusion Criteria:

* Blood donors whose last turning up were between November 31, 2016 to November 31, 2019

Exclusion Criteria:

* Blood donors who were deferral by blood screening result and other situations. Blood donors who have indicated that they would not accept urgent recruitment.
Subjects Perceived as Embarrassing During a Consultation in General Medical Practice

Optimal medical care requires transparency and honesty. However, it is not always easy to address some issues that may be considered too personal, intimate or taboo, such as mental health, sexuality, addiction and death. Patients' approach to these issues may be influenced by the profile of their general practitioner, or by the atmosphere of the consultation.

This retention of information by the patient, whether voluntary or not, can lead to adverse events related to care due to a misunderstanding between doctor and patient.

The main objective is to describe the proportion of patients limiting the subjects addressed during a general medicine consultation by gene, modesty and/or fear of judgment The secondary objective is to study the factors associated with limitation of subjects addressed by patient by gene, modesty and/or fear of judgment during a general medicine consultation.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years of age
* Agreeing to take part in the study

Exclusion Criteria:

* Minors
* Protected by law (guardianship, curatorship, safeguard of justice)
* Refusing to take part in the study
The Study of Regional Lung Ventilation-perfusion by EIT

This is a prospective observational trial. The purpose of this study is to explore the feasibility of EIT monitoring pulmonary blood flow and the consistency and difference between EIT monitoring pulmonary local ventilation blood flow and SPECT and CTPA monitoring methods


Eligibility Criteria:
Inclusion Criteria:

1. Admission to ICU was less than 72 hours;
2. Age ≥ 18 years old and ≤ 80 years old;
3. Volunteer to participate after communicating with patients' family members;

Exclusion Criteria:

1. The patients with heart implants could not be monitored by EIT;
2. Patients or their families refused to participate in the study;
3. Hypernatremia
Point-of-care Testing of Respiratory Pathogens at Pediatric Emergency Room

The main objective of the trial is to evaluate the effect of point-of-care testing of respiratory pathogens at a pediatric emergency room on the antibiotic consumption and hospital admissions in acutely ill children.

The study is a randomized controlled trial including children 0 up to 17 years of age with fever or acute respiratory infection at a pediatric emergency department in university hospital. In total 1668 subjects will be randomly allocated to undergo point-of-care multiplex respiratory pathogen testing with results ready within approximately one hour or to a control group with testing according to clinical judgement and results ready within next office day. Subjects will be randomized on admission and unequal allocation ratio of 2:1 (1112 subjects to intervention and 556 subjects to control arm) will be used. Data on rate of hospitalization, antibiotic prescriptions, ancillary testing and length of visit will be collected using medical record system.

Eligibility Criteria:
Inclusion Criteria:

* Any respiratory symptom defined as tachypnea, shortness of breath, apnea, wheezing, cough, rhinitis, croup, sneezing, ear ache, or sore throat AND/OR
* Fever \> 38.0 C

Exclusion Criteria:

* Need of resuscitation at emergency room
* Need of immediate transfer to pediatric intensive care unit
Comparison of the Postoperative Analgesic Efficacy of SPSIPB and ISBPB

Shoulder arthroscopy is one of the common surgical procedures performed today. After shoulder surgery, providing adequate analgesia is necessary for both the comfort of the patient and the ability to perform the necessary post-operative rehabilitation exercises early and regularly.

Nerve blocks reduces opioid consumption in the postoperative period by providing better pain control and therefore has advantages such as fewer side effects and less risk of pulmonary and cardiac complications.

In this study; it was aimed to compare the analgesic effectiveness of interscalene brachial plexus block and serratus posterior superior intercostal plane block, with each other and with the control group in the postoperative period in patients who underwent shoulder arthroscopy.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-80 years
* American Society of Anesthesiologists (ASA) score I-II-III
* Body Mass Index (BMI) between 18-30 kg/m2

Exclusion Criteria:

* Patients under 18 and over 80 years of age
* ASA score IV and above
* Patients with a history of bleeding diathesis
* BMI below 18 or above 30 kg/m2
Investigating a Model for Acute Ischemic Pain in Humans

The pathophysiology of acute ischemic pain is not well established. The aim of the present study was to investigate acute ischemic pain in humans with a view to establish a scientific model to perform future studies. The investigators examined whether peripheral nerve damage and acute inflammation occur during short episodes of acute ischemia.


Eligibility Criteria:
Inclusion Criteria:

* patients over 40 years
* unilateral femoral-popliteal PAD, Fontaine grade II

Exclusion Criteria:

* patients with pain at rest or other pain origin
* diabetic polyneuropathy
* deep vein thrombosis
Educational Intervention for Better Nutrition to Preserve Functionality - Design of a Randomised Clinical Trial

This project explores whether access to a digital education video can improve the nutritional situation of home-living older adults after being discharged from the hospital.


Eligibility Criteria:
Inclusion Criteria:

* Surgical patients embedded in a regional hospital.
* Home-living in one of nine selected municipalities.
* Be able to read and understand Norwegian.
* Have a consent competence.
* Have a body mass index \< 24.
* Have access to a digital solution such as a tablet or phone.

Exclusion Criteria:

* Persons given only a liquid diet.
* Persons in a terminally ill phase.
Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain

Although opioid rotation is well known treatment modality in reducing pain and opioid-induced neurotoxicity, it is not established whether opioid rotation is more appropriate or opioid escalation is more effective in controlling significant pain in cancer patients under opioid medication.

- The purpose of this study is to determine effective therapy out of opioid rotation and opioid dose escalation in patients with moderate to severe cancer pain who have been already treated with strong opioid.


Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years
* patients who are being treated with one of strong opioids including oral oxycodone, oral hydromorphone, or fentanyl patch with range from 60 mg to 200 mg of oral morphine equivalent daily dose (MEDD)
* moderate to severe cancer pain (numeric rating scale more than 3) at screening
* patients without uncontrolled adverse effects associated with currently applied opioid

Exclusion Criteria:

* previous opioid rotation
* unable to take oral medication
* life expectancy less than a month
* newly started chemotherapy and/or radiotherapy within past 2 weeks of screening
* serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase \> 2.5 times of upper normal limit
* serum total bilirubin or creatinine \> 1.5 times of upper normal limit
Ultrasound Guided Serratus Anterior Versus Erector Spinae Block in Pain Alleviation in Acute Herpes Zoster

Acute herpes zoster pain is very severe . Conventional analgesics may be of no value. Regional blocks may play a role


Eligibility Criteria:
Inclusion Criteria:

* Adult population between 30 and 75 years old.
* Unilateral painful thoracic herpetic eruption of less than one week duration.
* VAS more than or equal 4, persistent pain in spite of proper antiviral and analgesic therapy, (800 mg oral acyclovir, 5 times per day, for one week), pregabalin 300 mg per day, acetaminophen 1000 mg per day, topical calamine lotion).

Exclusion Criteria:

* Diabetic patients.
* Painful herpetic eruptive vesicles more than one week.
* Abdominal herpetic eruptions.
* Non-compliant on anti-viral (bulbar palsy for example).
* Co-malignancy or radiotherapy.
* Steroid therapy \> 5 mg prednisolone or its equivalent.
* Infections or hematoma at site of injection.
* Coagulopathy (chronic kidney or liver disease, clopidogrel use).